Sarah Schrieber, Pharm.D.
Senior Clinical Pharmacology Reviewer, Office of Clinical Pharmacology, Center for Drug Evaluation and Research, U.S. Food and Drug Administration
Dr. Schreiber received a bachelor’s in cell and molecular biology from Missouri State University and a bachelor’s in pharmacy and Pharm.D. from St. Louis College of Pharmacy. She completed a general pharmacy practice residency at Cox Health Systems in Springfield, Missouri, and a postdoctoral fellowship in drug development at the University of North Carolina at Chapel Hill and United Therapeutics Corporation in Research Triangle Park, North Carolina. During her fellowship, Dr. Schrieber studied the pharmacokinetics of silymarin in patients with different types and stages of liver disease.
Since joining the U.S. Food and Drug Administration in 2008, Dr. Schrieber has reviewed numerous small molecule and biologic oncology products. Current topics of interest include the evaluation of the impact of biologic products on the QTc interval, biosimilar drug development, and pharmacokinetic/ pharmacodynamic relationships of oncology drug products. She is committed to advancing public health through innovation of regulatory science.